

Lepidium Sativum Extract versus Simvastatin as an Adjunctive Local Delivery Agents to Non-Surgical Periodontal Therapy: A Randomized Controlled Clinical Trial with Biochemical Analysis

Ayman M. Al-kousyeer¹, Hala Abuelela¹, Suzan Sarhan¹, Olfat G. Shaker²,
Dina A. Osman³,

¹(Department of Oral Medicine, Periodontology, Oral Diagnosis and Radiology, Faculty of Dentistry, Ain Shams University, Egypt)

²(Department of Medical Biochemistry and Molecular Biology, Faculty of Medicine, Cairo University, Egypt)

³(Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy (Girls), Al Azhar University, Egypt)

Abstract

Background: Adjunctive local periodontal therapy is one of the best options to improve the health of the pocket tissue. The comparison of local effects of simvastatin and *Lepidium sativum* as an aid in reinforcing the healing of periodontal tissue is a point of importance. The objective of this work was to evaluate the effectiveness of the local application of *Lepidium sativum* versus simvastatin gel on clinical parameters and nuclear factor kappa B biomarker.

Subjects and methods: The current study was conducted on thirty patients selected in this study with localized periodontitis stages (II, and III) and grade (A). Patients have haphazardly divided into two groups; with fifteen subjects in each. Group (I): (Control group) candidates treated with scaling and root surface debridement with local delivery of 1.2% of simvastatin gel. Group (II): (Test group) they were treated with scaling and root surface debridement with local delivery of *Lepidium sativum* gel. Clinical and biochemical indices were gathered at time intervals; baseline (after 1 week from the last debridement), 1 month, and 3 months postoperatively.

Results: Statistical results of our study showed advancement in MSBI, PD, and CAL parameters in both groups (I) and (II) after 1 month and 3 months follow-ups. There was a higher significant minimization in NF- κ B level in the SMV group in comparison with the LS group.

Conclusion: Hence, we concluded from this present study that the test group has almost similar significant impact to the control one on the periodontal disease indicators as an adjunctive agent to non-surgical therapy, which requires more investigations and different concentrations used for LS efficacy.

Keywords: Periodontitis; Non-surgical therapy; *Lepidium sativum*; Simvastatin, Nuclear factor kappa B.

Date of Submission: 05-12-2022

Date of Acceptance: 17-12-2022

I. Introduction

Periodontal disease is a common oral disease that is characterized by severe inflammation and destruction of the periodontal attachment apparatus. The disease involves a wide range of endemic inflammatory conditions that affect the supporting structures of teeth (clinical attachment and bone loss) leading to tooth loss and inflammation of the system. The pathogenesis of periodontitis is characterized by microbial-associated, host-mediated inflammation that leads to the destruction of periodontal tissue (Kinane et al., 2017).

In an effort to align it with arising scientific evidence; the classification of periodontitis had been frequently updated. The 2017 world workshop accepted that three types of periodontitis can be identified, consistent with current knowledge of pathophysiology: necrotizing periodontitis, periodontitis as a manifestation of systemic diseases, and types of the disease previously known as 'chronic' or 'aggressive' and now grouped into a single category, 'periodontitis'. This modern classification is also based on multi-dimensional staging and grading systems according to the severity, complexity, distribution, rate of progression, and modifiable risk factors (Caton et al., 2018).

The pathogenesis of periodontitis includes antagonistic actions between subgingival biofilm and host immune response causing a loss of balance between the virulence of bacteria and the host defense and leading to changes in the function and structure of the periodontium. The bacterial plaque has a major role in exacerbating these responses and causing the disease (Cekici et al., 2014).

NF- κ B plays a major role in soft tissue inflammation and collagen degradation through MMP activation. Periodontal tissue remodeling is also mediated by the activation of NF- κ B- dependent genes encoding inducible forms of COX- 2 and iNOS enzymes participating in the production of prostaglandins, and NO and its metabolites. This factor also has another important function in bone destruction by stimulating osteoclast production. NF- κ B- dependent cytokines such as IL- 1 α and IL- 1 β , TNF- α , IL- 6, and IL- 17 induce osteoclast differentiation and activation mediated by RANK (Gözl *et al.*, 2015).

Although Non-surgical periodontal therapy (NSPT) is considered the gold standard and the first route to periodontal disease management, its inability to completely eliminate periodontal pathogens from the soft and hard tissue surfaces and may cause re-colonization leads to reinfection. To overcome these deficiencies, adjunctive use of systemic or local chemotherapeutic agents becomes an indispensable treatment modality (Ehizele *et al.*, 2013).

The rationale for using locally delivered drugs (LDD) in periodontal disease is to chemically kill or reduce the plaques within the biofilm in the pocket. This is achieved by applying high concentrations of an antibiotic or antiseptic in direct contact with the root surface without remarkable systemic effect (Arunachalam *et al.*, 2017).

Statins such as simvastatin (SMV) have been considered as an ancillary remedy to non-surgical periodontal therapy. Statins were initially imported as cholesterol-reducing drugs, which were performed by hindering the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase. Statins also have additional properties including; anti-inflammatory, antioxidant, antibacterial, and other pleiotropic effects such as blocking the release of pro-inflammatory mediators and matrix metalloproteinases (MMPs). Therefore, statins have been shown to promote bone formation and have proven to be effective in periodontal therapy (Zeiser, 2018).

There are many researchers who use plants without any regard for their benefits, efficacy, safety, and therapeutic prominence. *Lepidium Sativum* (LS) is an annual, edible herb belonging to the family of Brassicaceae. It was found in many countries such as Saudi Arabia, India, and Egypt. It had other names such as Garden cress and Hab Al-Rashad (Prajapati *et al.*, 2014; Moro *et al.*, 2018).

LS is composed of seeds, leaves, and roots. LS seeds contain many several phenols, minerals, proteins, and fatty acids. LS oil (LSO) which is extracted from seeds, consisting primarily of polyunsaturated fatty acids (linolenic acid (LA) and α -linolenic acid (ALA)). Due to its high antioxidant and phytosterol content, this oil is relatively stable leading to a decrease in reactive oxygen species (ROS) generation and their nitric oxide metabolites (Al-Sheddi *et al.*, 2016).

LS extract can be used in many therapeutic domains as an anti-hyperglycemia, anti-hyperlipidemia, anti-diarrhea, anti-rheumatic, hepatoprotective, anti-oxidant, anti-inflammatory, and anti-microbial and in gastrointestinal, skin and airway diseases and some bone fractures healing. Moreover, LS is used in common medically to treat inflammatory diseases such as hepatitis, diabetes mellitus and joint inflammation (Shabbir *et al.*, 2018).

II. Subjects And Methods

Study Design: This study was designed as a randomized, controlled, and phase (IV) clinical trial using computer-generated random tables. The patients, researcher, and outcome assessor were blinded from the type of intervention.

Patient selection and grouping: Thirty periodontitis patients were chosen from the out-patient clinic of Oral Medicine, Periodontology, Oral Diagnosis and Radiology Department, Faculty of Dentistry, Ain Shams University. Total number of patients was randomly divided into two groups:

Group I (Control group): included (15) patients with stage II and III, grade A periodontitis; were treated with scaling and root surface debridement followed by application of 1.2% simvastatin gel.

Group II (Test group): included (15) patients with stage II and III, grade A periodontitis; were treated with scaling and root surface debridement followed by application of *lepidium sativum* gel.

Patients were selected considering the following criteria : (they were free from any systemic disease according to the modified Burkett's health history questionnaire, both genders with age ranged from 25-50 years, pocket depth ≥ 5 mm with horizontal bone loss and less than 30% of teeth were affected, and must be able to return to recall visits). Smokers, pregnant and lactating women, prisoners or abused individuals, uncooperative patients, patients with history of allergy, and previous periodontal treatment or any use of antibiotic/anti-inflammatory drugs within the last 6 months were excluded from this study.

All patients in this study were received conventional scaling and root debridement using hand and ultrasonic instruments followed by oral hygiene instructions. The study was approved by the Research Ethical Committee,

Faculty of Dentistry, Ain Shams University. All eligible patients were thoroughly learned of the nature, possible risks and their auxiliary aids in the research and signed written informed consent documents. The whole study was carried out from September 2021 to July 2022.

Methods:

Preparation of 1.2% simvastatin gel: A 4% methyl cellulose 4000 Cpsgel was prepared by dispersing 2 gm of methyl cellulose powder in 50 ml of hot distilled water 50 - 60 o C (as the methyl cellulose starts to melt at 65.7oC). 1.2mg of SMV was added to distilled water to produce 1.2% concentration of the drug in the gel. Continuous stirring is performed until cooling to obtain the gel form of homogeneous mixture of polymer and ensure complete dissolution of methyl cellulose, water and drug at room temperature. The produced gel is white in color with viscous nature(*Pradeep and Thorat 2010*).

Preparation of lepidium sativum in situ gel: Carbopol-poloxamer gel of LS was prepared by the cold method (Schmolk, 1972). Carbopol P940 (1% w/v) was firstly solved in non-ionized water using a magnetic stirrer. About (30% w/w) of LSO was added and stirred for 5 min at 200 rpm. After total dissolution, the solution was cooled in an ice bath, pluronic F127 (30% w/v) was then added slowly with continuous stirring. The mixture was transferred to fridge at 4 degree Celsius for 24 hours to ensure complete drying and removal of entrapped air bubbles(*Nasra et al., 2017*).

Local gel application into the periodontal pocket:LS and SMV gels were locally delivered in the deepest periodontal pockets. Local application of the gel was done at baseline. The area around the injected materials was isolated by cotton rolls. The two gels were injected into the pockets using a syringe with blunted needle. The pockets were filled until the materials were detected at the gingival margin (*Agarwal et al., 2016*).

Figure (1): application of LS gel using a plastic blunted tip



Gingival crevicular fluid sample collection:GCF samples were taken at baseline, 1 month, and 3 months after therapy. The GCF sample was collected by inserting periopaper (Oralflow Inc., Smithtown, NY, USA) parallel to the long axis of the tooth, into the sulcus/pocket for 30s until a minimal resistance was felt. Periopaper strips visually contaminated with blood and saliva were discarded. Level of nuclear factor kappa b in GCF samples will be determined by using a commercially available means of Enzyme Linked Immune sorbent Assay (ELISA) (*Escobar et al., 2018*).

Figure (2): Insertion of a periopaper strip parallel to the long axis of the tooth, just 0.5 mm into the sulcus, and kept for 30 seconds for GCF sample collection



Clinical assessment: The periodontal conditions of each patient were evaluated at baseline and after 3 months follow-up. Plaque Index (PI) used to assess plaque accumulation around gingival margin. Mean Sulcus Bleeding Index (SBI) used to assess gingival inflammation. Probing Depth (PD) and Clinical Attachment Level (CAL) were measured by the University of Mish O'probe with Williams' graduations. The Occlusal stent was used as an auxiliary tool for the proper placement of the probe.

Figure (3):Measurement of probing pocket depth equal to 5mm using the University of Mish O'probe with stent placement



III. Results:

This clinical trial was done in 30 patients with a mean age of 35.5 years whom suffered from mild to moderate periodontitis. All of them continued the study with no allergic reactions or any adverse effects.

A. Clinical evaluation:

Regarding oral hygiene status, plaque index score (PI) in both groups of the study was showed a significant advancement of plaque amount condition at baseline. However, PI showed no significant improvement in each group after 3 months of the treatment. By comparing the two studied groups, there was no statistically significant difference between them at baseline and after 3 months of therapy. (Table 1, figure 4)

Additionally, the test and control groups showed no significant decrease in the mean sulcus bleeding index (MSBI) at baseline. While these two studied groups showed significant advancement in SBI and improvement in the bleeding status after 3 months of treatment. But in spite of all that, when comparing both groups there was no noticeable difference at baseline and after 3 months follow up. (Table 1, figure 4)

Furthermore, the reduction of probing depth (PD) and clinical attachment level (CAL) were statistically significant within test and control groups from baseline until 3 months. Thus, the periodontal condition was improved after intervention in each group. When comparing SMV versus LS intended, the reduction in PD and CAL at each investigation period was not statistically significant. (Table 1, figure 4)

Table (1): Mean and standard deviation (SD) for PI, MSBI, PD, and CAL percentage change (%) for two studied group at baseline and after 3 months follow up:

Measurement	Percentage change (%) (Mean±SD)		p-value
	Simvastatin group	Lepidium Sativum group	
PI	0.25±0.50	0.50±0.71	0.780ns
MSBI	0.86±0.21	0.81±0.21	0.552ns
PD	0.42±0.08	0.35±0.09	0.063ns
CAL	0.35±0.09	0.30±0.14	0.583ns

*; significant ($p \leq 0.05$) ns; non-significant ($p > 0.05$)




Figure (4):Bar chart showing average PI, MSBI, PD, and CAL percentage change (%) for two studied group at baseline and after 3 months follow up

B. Biochemical evaluation:

Regarding the change in the level of NF-κB between two studied groups, SMV group showed higher values at two time interval (baseline-1 month) and (baseline- 3month) than LS group. But the statistical difference was not significant. Also, there is no statistically substantial difference between two groups at time interval (1 month – 3 month).(Table 2, figure 5)

Table (2): Mean and standard deviation (SD) for NF-κB percentage change (%) for two studied groups

Interval	NF-κB percentage change(%) (Mean±SD)		p-value
	Simvastatin group	Lepidium Sativum group	
Baseline- 1 month	24.63±6.50	19.69±7.36	0.071ns
1-3 months	37.74±13.82	36.62±7.00	0.789ns
Baseline- 3 months	53.59±8.48	49.10±7.48	0.149ns

*; significant (p ≤ 0.05) ns; non-significant (p>0.05)




Figure (5): Bar chart showing average NF-κB percentage change (%) for the two studied groups

IV. Discussion

The primary aim of periodontal therapy is to inhibit fragmentation and replaces the periodontal apparatus with its initial form and structure. Non-surgical periodontal therapy (NSPT), including scaling and root surface debridement (SRD), has been suggested as the ideal initial treatment for patients suffering from periodontitis. This phase I therapy alone cannot guarantee remission of the disease and achieve healing of tissue completely. Hence, SRD should be augmented with adjunctive methods systemically or locally (*Laleman et al., 2017; Graziani et al., 2018*).

Local delivery of antibacterial therapeutic agents in periodontitis can be effective when they are placed directly in periodontal pockets. LDD has numerous properties including minimally invasive, direct application at the site of infection, avoidance of gastrointestinal issues, and devaluation in the dose. The essential advantage is that the drug has a higher concentration than the minimum inhibitory concentration (MIC) after being delivered into the pocket and persists for up to several weeks (*Szulc et al., 2018; Rajeshwari et al., 2019*).

The host modulation treatment (HMT) aims to reduce periodontal tissue damage and stabilize or even regenerate periodontium. This can be achieved by improvements in themodulatory behavior of immune responseagainst perio-pathogens. HMT can improve therapeutic outcomes, slow the progression of the disease, allow for more predictable management of patients, and possibly even work as a preventive agent against the development of periodontitis (*Deore et al., 2014; Sulijaya et al., 2019*).

LS accelerates the speed of bone fracture healing. It possesses strong pharmacological properties which resemble those of non-steroidal anti-inflammatory drugs (NSAIDs). It was suggested that the extract produced anti-inflammatory and anti-ulcerative effects by inhibiting *P.g* synthesis like other NSAIDs (*ElSayed et al., 2017*).

According to a new study by *Bathish et al., 2021*,Lepidium sativum seeds possess strong pharmacological properties which are anti-inflammatory immune-modulatory effects. In addition, due to the antioxidant properties of seeds, the beneficial effect of LS on bone-forming cells relies on the phenolic content in the seeds of garden cress (GCS) essentially Tocopherols. They contribute to disease prevention, besides having an essential nutritional role as a source of vitamin E for humans.In addition,L.S has immunomodulatory properties and wound healing activities. It decreases nuclear factor (NF-κB), nitric oxide (NO), COX-2 and leukotriene B4 (LB4) which are thought to play roles in the pathogenesis of inflammatory diseases. L. sativum prevented the rise of RANKL/OPG ratio, which is an essential component in the regulation of bone metabolism (*Abdallah et al., 2020*).

The anti-inflammatory effect of SMV comes from the down-regulating expression of the pro-inflammatory cytokines such as IL-1 β , IL-6, IL-8, and TNF- α and decrease levels of tissue destruction mediators like as MMP-1, 3, 8, 9, and 13 through inhibiting activation of NF- κ B that regulates the expression of diverse inflammatory cytokines and destructive enzymes. The anti-inflammatory effect of simvastatin as a locally delivered chemotherapeutic agent showed a substantial improvement in the clinical indicators of periodontal disease. Also, SMV has an antimicrobial effect which is considered to be the best statin against periodontal pathogens such as *P.gingivalis* and *A.a*. In addition, some studies have proved that statins have the capability to elevate levels of both OPG and BMP-2; and inhibit RANK/RANKL factors. Thus SMV can hinder bone resorption, and encourage osteoblast differentiation and neovascularization (Martande et al., 2017; Roca-Millan et al., 2019; Gupta et al., 2019; Rajagopal et al., 2021).

A recent study confirmed the impact of SMV and LS with NSPT on the RANKL/OPG ratio in the crevicular fluid. The effects of RANKL are blocked by its soluble decoy receptor osteoprotegerin (OPG), thus inhibiting osteoclast differentiation, activation, and survival (Rajagopal et al., and Hegazy et al., 2021).

Regarding PI score, it was recorded that the LS group (which is the test one) showed higher PI than the SMV group (which is the control one) after 3 months of treatment in comparison with baseline, which is after one week of the last SRD, but this difference was not statistically significant between the two studied groups. In addition, the mean difference and percentage change in SMV are not significantly different from that of LS. Therefore, it was noticed that patients strove to be compliant and follow proper oral hygiene instructions.

These results are in accordance with Vijayapremakumar et al., 2021 who noted a slight increase in plaque scores after 90 days. This might be due to the reduction in the concentration of the drug. None of the patients reported any long-term side effects and no adverse reactions were observed during the study.

Despite the mean percentage change of MSBI showing no statistically substantial difference between these groups after 3 months of follow-up, there was a statistically significant decrease in each of the two studied groups from baseline to after 3 months with a little advantage for the LS group. This was due to the resolution of the inflammation and reduction of pro-inflammatory markers. This result is similarly coinciding with a study conducted by Gupta et al., 2021 who demonstrated that a significant reduction in clinical signs of inflammation can be achieved by NSPT in combination with SMV in patients with chronic periodontitis.

Furthermore, studies conducted by El Kilani, et al., 2019 and Bathish et al., 2021 showed clinically the important role of LS seeds powder extract with local debridement. The bleeding index was significantly reduced after 3 and 6 months follow-up periods.

With reference to probing depth (PD), the results of the present study showed a significant decrease in pocket depth in both groups from baseline to three months. However, by comparing the study group with the control one, there was no statistically significant difference between them at baseline. After 3 months, SMV showed a more significant decrease in PD than LS. Although the mean percentage degree of PD showed a significant decrease in the SMV group, there was no statistically substantial difference between the two studied groups. These results are compatible with the studies demonstrated by Donos et al. 2020 and Cecoro et al., 2021 who showed a significant reduction in PPD after local application of 1.2% SMV combined with NSPT at time intervals from baseline up to 3 months.

Moreover, in agreement with a study demonstrated by Bathish et al., 2021, the local delivery of LS gel showed a significant decrease in PD after 3 months of treatment. This study indicated that LS gel was applied twice to ensure its efficacy.

In our study, the clinical attachment loss was decreased significantly in each group with a slight preference for the SMV group after 3 months of treatment. Thus clinical attachment level was gained after 3 months postoperatively. Despite that, there was no statistically significant difference in the mean difference and percentage degree of CAL between the test and control groups at two-time intervals. This improvement of CAL in each group was noticed in a study by Vemanaradhya et al., 2017 who confirmed that SMV is ranked the best in CAL gain than among statins family. Another recent study was done by Bathish et al., 2021 who showed that *Lepidium sativum* extract gel can result in a significant reduction in clinical attachment loss and CAL gain.

By comparing NF- κ B (ng/ml) levels between the study and control group, each one of these two groups showed a significant decrease in inflammatory marker value from baseline to after 3 months follow up. The mean difference revealed that the SMV group showed significant differences at time intervals (baseline-1 month) and (baseline-3 months). But in the time interval from one month to three months, there was no statistically substantial difference between L.S and SMV groups. In spite, SMV had higher change than LS at three-time intervals (baseline, 1 month, and 3 months); the mean percentage change of NF- κ B demonstrated that there was no statistically significant difference between the two groups of the study.

These results are in accordance with a study done by Hegazy et al., 2021 who proved the efficacy of L.S in decreasing the expression of NF- κ B through their effects on markers of inflammation such as IL-6 and TNF- α which played a fundamental role in bone degradation and inflammation.

A systematic review conducted by *Petit et al., 2019* showed the importance of statins such as SMV in the suppression of severe pathways in inflammation including NF- κ B activation. In addition, this study confirmed that osteoclastogenesis was decreased by down-regulation of RANKL/RANK signaling and NF- κ B.

V. Conclusion

Within the limitations of the current study, we concluded that locally delivered LS and SMV can be used as effective local adjunctive agents to NSPT because of their important direct impact on periodontitis clinical parameters and NF- κ B level reduction. In addition, we also recommended more studies and investigations to evaluate multiple applications and different concentrations of LS in situ gel in the management of periodontitis.

References

- [1]. **Kinane DF, Stathopoulou PG, Papapanou PN.** Periodontal diseases. *Nat Rev Dis Primers* [Internet]. 2017;3:17038. Available from: <http://dx.doi.org/10.1038/nrdp.2017.38>
- [2]. **Caton JG, Armitage G, Berglundh T, Iain LC, Chapple S, Jepsen KS, et al.** A new classification scheme for periodontal and peri-implant diseases and conditions-Introduction and key changes from the 1999 classification. *Journal of Clinical Periodontology*. 2018;45(45).
- [3]. **Cekici A, Kantarci A, Hasturk H, Van Dyke TE.** Inflammatory and immune pathways in the pathogenesis of periodontal disease. *Periodontology*. 2000. 2014 Feb;64(1):57–80.
- [4]. **Gölz L, Memmert S, Rath-Deschner B, Jäger A, Appel T, Baumgarten G, et al.** Hypoxia and *P. gingivalis* synergistically induce HIF-1 and NF- κ B activation in PDL cells and periodontal diseases. *Mediators Inflamm* [Internet]. 2015;2015:438085. Available from: <http://dx.doi.org/10.1155/2015/438085>
- [5]. **Ehizele A, Akhionbare O.** Effect of non-surgical periodontal therapy on the concentration of volatile sulfur compound in mouth air of a group of Nigerian young adults. *Ann Med Health Sci Res*. 2013;3:433–7.
- [6]. **Arunachalam R, Rajeev V, Vedam V, Ganapathy S, Dhanavel J.** —Perioceutics in the management of Periodontal Disease. *J Young Pharm*. 9(1):8-13., 2017
- [7]. **Rajeshwari HR, Dhamecha D, Jagwani S, Rao M, Jadhav K, Shaikh S.** Local drug delivery systems in the management of periodontitis: A scientific review. *J Control Release*. 2019;307:393–409.
- [8]. **Zeiser R.** Immune modulatory effects of statins. *Immunology* [Internet]. 2018;154(1):69–75. Available from: <http://dx.doi.org/10.1111/imm.12902>
- [9]. **Prajapati VD, Maheriya PM, Jani GK, Patil PD, Patel BN.** *Lepidium sativum* Linn.: A current addition to the family of mucilage and its applications. *Int J Biol Macromol* [Internet]. 2014;65:72–80. Available from: <http://dx.doi.org/10.1016/j.ijbiomac.2014.01.008>
- [10]. **Moro MG, Silveira Souto ML, Franco GCN, Holzhausen M, Pannuti CM.** Efficacy of local phytotherapy in the nonsurgical treatment of periodontal disease: A systematic review. *J Periodontal Res* [Internet]. 2018;53(3):288–97. Available from: <http://dx.doi.org/10.1111/jre.12525>
- [11]. **Al-Sheddi ES, Farshori NN, Al-Oqail MM, Musarrat J, Al-Khedhairi AA, Siddiqui MA.** Protective effect of *Lepidium sativum* seed extracts against hydrogen peroxide-induced cytotoxicity and oxidative stress in human liver cells (HepG2). *Pharm Biol*. 2016;54(2):314–21.
- [12]. **Shabbir F, Eddouks M, Nadeem F, Azeem MW.** A brief review on bioactivities and therapeutic potentials of garden cress (*Lepidium sativum* L.). *International Journal of Chemical and Biochemical Sciences*. 2018;13:36–45.
- [13]. **Pradeep AR, Thorat MS.** Clinical effect of subgingivally delivered simvastatin in the treatment of patients with chronic periodontitis: a randomized clinical trial. *Journal of periodontology*. 2010 Feb;81(2):214-22.
- [14]. **Nasra MM, Khiri HM, Hazzah HA, Abdallah OY.** Formulation, in-vitro characterization and clinical evaluation of curcumin in-situ gel for treatment of periodontitis. *Drug delivery*. 2017 Jan 1;24(1):133-42.
- [15]. **Agarwal S, Chaubey KK, Chaubey A, Agarwal V, Madan E, Agarwal MC.** Clinical efficacy of subgingivally delivered simvastatin gel in chronic periodontitis patients. *Journal of Indian Society of Periodontology*. 2016 Jul;20(4):409.
- [16]. **Escobar GF, Abdalla DR, Beghini M, Gotti VB, Rodrigues Junior V, Napimoga MH, et al.** Levels of pro and anti-inflammatory cytokines and C-reactive protein in patients with chronic periodontitis submitted to nonsurgical periodontal treatment. *Asian Pac J Cancer Prev* [Internet]. 2018;19(7):1927–33. Available from: <http://dx.doi.org/10.22034/APJCP.2018.19.7.1927>
- [17]. **Papapanou PN, Sanz M, Buduneli N, Dietrich T, Feres M, Fine DH, et al.** Periodontitis: Consensus report of workgroup 2 of the 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions: Classification and case definitions for periodontitis. *J Clin Periodontol* [Internet]. 2018;45 Suppl 20:S162–70. Available from: <http://dx.doi.org/10.1111/jcpe.12946>
- [18]. **Laleman I, Cortellini S, De Winter S, Rodriguez Herrero E, Dekeyser C, Quirynen M, et al.** Subgingival debridement: end point, methods and how often? *Periodontol 2000* [Internet]. 2017;75(1):189–204. Available from: <http://dx.doi.org/10.1111/prd.12204>
- [19]. **Graziani F, Karapetsa D, Mardas N, Leow N, Donos N.** Surgical treatment of the residual periodontal pocket. *Periodontol 2000* [Internet]. 2018;76(1):150–63. Available from: <http://dx.doi.org/10.1111/prd.12156>
- [20]. **Szulc M, Zakrzewska A, Zborowski J.** Efficacy of local drug delivery in periodontitis treatment. *Dent Med Probl*. 2018;55(3):331–40.
- [21]. **Deore GD, Gurav AN, Patil R, Shete AR, Naiktari RS, Inamdar SP.** Omega 3 fatty acids as a host modulator in chronic periodontitis patients: a randomised, double-blind, placebo-controlled, clinical trial. *J Periodontal Implant Sci* [Internet]. 2014;44(1):25–32. Available from: <http://dx.doi.org/10.5051/jpis.2014.44.1.25>
- [22]. **Sulijaya B, Takahashi N, Yamazaki K.** Host modulation therapy using anti-inflammatory and antioxidant agents in periodontitis: A review to a clinical translation. *Arch Oral Biol* [Internet]. 2019;105:72–80. Available from: <http://dx.doi.org/10.1016/j.archoralbio.2019.07.002>
- [23]. **Martande SS, Kumari M, Pradeep AR, Singh SP, Suke DK.** Comparative evaluation of efficacy of subgingivally delivered 1.2% Atorvastatin and 1.2% Simvastatin in the treatment of intrabony defects in chronic periodontitis: a randomized controlled trial. *Dental Clinics, Dental Prospects*. 2017;11(1).

- [24]. **Vemnaradhya GG, Emami S, Mehta DS, Bhandari S.** Effect of 1.2% of simvastatin gel as a local drug delivery system on Gingival Crevicular Fluid interleukin-6 & interleukin-8 levels in nonsurgical treatment of chronic periodontitis patients. *Archives of Oral Biology*. 2017;82:55–61.
- [25]. **Kumar V, Tomar V, Ranade SA, Yadav HK, Srivastava M.** Phytochemical, antioxidant investigations and fatty acid composition of *Lepidium sativum* seeds. *Journal of Environmental Biology*. 2020;41(1):59–65.
- [26]. **ElSayed H, Elkilani N, Farid M.** The effects of different extract of *Lepidium Sativum* on induced periodontitis in dexamethasone immunosuppressed rats. *Al-Azhar Dent J Girls* [Internet]. 2017;4(3):249–53. Available from: <http://dx.doi.org/10.21608/adjg.2017.5265>
- [27]. **Bathish Y, El Kilani N, Dawaba A, Farid Z.** Effect of *Lepidium Sativum* Gel as an Adjunct to Non-Surgical Treatment in Management of Periodontitis Patients Stage. *Al-Azhar Dental Journal for Girls*. 2021;8:285–92.
- [28]. **Abdallah HM, Farag MA, Algendaby MM, Nasrullah MZ, Abdel-Naim AB, Eid BG, et al.** Osteoprotective activity and metabolite fingerprint via UPLC/MS and GC/MS of *Lepidium sativum* in ovariectomized rats. *Nutrients* [Internet]. 2020;12(7):2075. Available from: <http://dx.doi.org/10.3390/nu12072075>
- [29]. **Roca-Millan E, González-Navarro B, Izquierdo-Gómez K, Marí-Roig A, Jané-Salas E, López-López J, et al.** The application of statins in the regeneration of bone defects. Systematic review and meta-analysis. *Materials (Basel)* [Internet]. 2019;12(18):2992. Available from: <http://dx.doi.org/10.3390/ma12182992>
- [30]. **Gupta S, Del Fabbro M, Chang J.** The impact of simvastatin intervention on the healing of bone, soft tissue, and TMJ cartilage in dentistry: a systematic review and meta-analysis. *Int J Implant Dent* [Internet]. 2019;5(1):17. Available from: <http://dx.doi.org/10.1186/s40729-019-0168-4>
- [31]. **Rajagopal A, ANAND M.** The Role of Statins in Periodontal Therapy—A Review. *Cumhuriyet Dental Journal*. 2022;25(2):200–5.
- [32]. **Hegazy E, Haggag T, Elmansy M.** The Protective role of *Nigella sativa* versus *Lepidium sativum* on the submandibular salivary gland in hypercholesterolemic albino rat (Histological and Immunohistochemical study). *Egypt Dent J* [Internet]. 2021;67(4):3113–25. Available from: <http://dx.doi.org/10.21608/edj.2021.77526.1649>
- [33]. **Vijayapremakumar VK, Professor, Department of Periodontics, College of Dental Sciences, Davangere, Karnataka, India, Mehta A, Shivanand P, Prakash S,** Post Graduate Student, Department of Periodontics, College of Dental Sciences, Davangere, Karnataka, India, et al. Nature's Anti-inflammatory agent and its use as a Local drug delivery agent for treatment of chronic periodontitis: A clinical, microbiological and biochemical study. *J Ayurvedic herb med* [Internet]. 2021;7(1):30–5. Available from: <http://dx.doi.org/10.31254/jahm.2021.7107>
- [34]. **Elhennawy E, Hammad A, Bilal M.** Effect of Adjunctive Use of Simvastatin Gel in Management of Periodontitis on the Crevicular Fluid Calproteins Levels. *Egyptian Dental Journal*. 2022 Apr 1;68(2):1455-64.
- [35]. **Gupta N, Verma S, Sharma S, Gill JS, Khurana A, Gupta S, et al.** Effectiveness of 1.2% Simvastatin gel as an adjunct to non-surgical therapy in the treatment of chronic periodontitis: A split mouth randomized controlled trial. *Int Health Res J* [Internet]. 2021;4(12):OR1–6. Available from: <http://dx.doi.org/10.26440/ihrj/0412.03396>
- [36]. **El Kilani NS, Hazzaa HH, Hemoud HES, Imam O.** Clinical and radiographic assessment of single or combined treatment with *Lepidium sativum* and alendronate of non-surgically treated chronic periodontitis in postmenopausal osteoporotic women. *J Int Acad Periodontol*. 2019;21(1):20–8.
- [37]. **Donos N, Calciolari E, Brusselaers N, Goldoni M, Bostanci N, Belibasakis GN.** The adjunctive use of host modulators in non-surgical periodontal therapy. A systematic review of randomized, placebo-controlled clinical studies. *Journal of clinical periodontology*. 2020 Jul;47:199-238.
- [38]. **Cecoro G, Piccirillo A, Martuscelli G, Del Fabbro M, Annunziata M, Guida L.** Efficacy of locally delivered statins as an adjunct to scaling and root planning in the treatment of periodontitis: a systematic review and meta-analysis. *Eur Rev Med Pharmacol Sci* [Internet]. 2021;25(18):5737–54. Available from: http://dx.doi.org/10.26355/eurrev_202109_26792
- [39]. **Petit C, Batool F, Bugueno IM, Schwinté P, Benkirane-Jessel N, Huck O.** Contribution of statins towards periodontal treatment: A review. *Mediators Inflamm* [Internet]. 2019;2019:6367402. Available from: <http://dx.doi.org/10.1155/2019/6367402>

Ayman M. Al-kousyee, et. al. "Lepidium Sativum Extract versus Simvastatin as an Adjunctive Local Delivery Agents to Non-Surgical Periodontal Therapy: A Randomized Controlled Clinical Trial with Biochemical Analysis." *IOSR Journal of Dental and Medical Sciences (IOSR-JDMS)*, 21(12), 2022, pp. 50-57.